Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment
Top Cited Papers
- 1 June 2006
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 7 (6) , 508-514
- https://doi.org/10.1016/s1470-2045(06)70726-4
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Synthesis and Biological Evaluation of 1‐Amino‐1,1‐bisphosphonates Derived from Fatty Acids Against Trypanosoma cruzi Targeting Farnesyl Pyrophosphate Synthase.ChemInform, 2006
- Bisphosphonates for Treatment and Prevention of Bone MetastasesJournal of Clinical Oncology, 2005
- The inhibitory effect of alendronate, a nitrogen‐containing bisphosphonate on the PI3K–Akt–NFκB pathway in osteosarcoma cellsBritish Journal of Pharmacology, 2005
- Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's DiseaseNew England Journal of Medicine, 2005
- Effects of short‐term alendronate on bone mineral density in haemodialysis patientsNephrology, 2005
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005
- Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapySupportive Care in Cancer, 2005
- A prospective randomized study for prevention of postrenal transplantation bone lossKidney International, 2005
- Pharmacokinetics/Pharmacodynamics of BisphosphonatesClinical Pharmacokinetics, 2005
- Bisphosphanates and Oral Cavity Avascular Bone NecrosisJournal of Clinical Oncology, 2003